arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Kura Oncology, Inc.

KURA
$10.87 ▼ -0.16 (-1.50%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
70 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Kura Oncology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $965.9M
Dividend Yield —
Revenue Growth 36.5% ↗
Op. Margin -349.8% ↗
ROIC -135.2% ↘
FCF / Share $-0.71 ↗
Trailing P/E —
Price / Book 20.0x
FCF Yield —
Debt / Equity 0.12
info Valuation on last close. End-of-day price, Sep 24, 2026.

70-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$20.87M
↑ +36.5% —
Net Income Profit after all expenses
$-73.33M
↓ -27.7% —
Operating Margin Operating profit as % of sales
-349.8%
↑ +18.9% 0th
FCF / Share Free cash flow per share
$-0.71
↑ +26.7% —
Long-Term Debt Long-term obligations
$5.57M
↓ -42.8% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns ↓
4
Financial Health →
47
Cash Quality ↓
31

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 19 years · 70 quarters